Abstract
Postingestive reward contributes to acquisition of food preferences, mediated by striatal dopamine, with assessment in humans, while challenging, suggesting blunted brain responses to postingestive nutrient stimulation in obesity. To perform postingestive conditioning in humans, we used carboxymethylcellulose, a food thickener, to optimize conditions where maltodextrin, an insipid carbohydrate, was not detectable by sensory cues (n=159). In the resulting Flavour Nutrient Conditioning protocol using flavoured yoghurts, where one flavour was paired with maltodextrin (+102 Kcal, CS+) and another with carboxymethylcellulose (+1.8 Kcal, CS-), we found that in healthy volunteers (n=52), preference for CS+ increased after conditioning, when assessed according to intake, with no effects on pleasantness scores. This protocol and [123I] IBZM SPECT, to assess availability of striatal dopamine D2-like receptors (DD2lR) were applied in a clinical study (n=61) with pre-bariatric candidates with obesity, weight-stable patients after surgery, and an additional group of healthy controls. Conditioning was conserved among participants in the clinical study, and did not differ significantly between the 3 groups. However, striatal DD2lR availability was reduced in patients from the obesity group, when compared both to healthy volunteers and the surgical group. Importantly, in exploratory analyses, DD2lR availability was strongly correlated with conditioning strength, as well as a measure of restrained eating, but only in patients with gastric bypass. These results suggest that postingestive reinforcement, while conserved in obesity and after bariatric surgery, may be associated to post-surgery recovery of central dopaminergic homeostasis and to changes in feeding behaviour after gastric bypass.
Competing Interest Statement
According to ICMJE guidelines for Disclosure of Potential Conflicts of Interest, none were reported by GR, ABF, FPMO, JSD, MO, CL, DCC and RMC. AJO-M was national coordinator for Portugal of a non-interventional study (EDMS-ERI-143085581, 4.0) to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd (2019-2020), national coordinator for Portugal of trials of psilocybin therapy for treatment-resistant depression, sponsored by Compass Pathways, Ltd (EudraCT number 2017-003288-36), and of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd (EudraCT NUMBER: 2019-002992-33); is recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests; received payment, honoraria or other support from Janssen, Angelini, MSD, Neurolite AG, and the European Monitoring Centre for Drugs and Drug Addiction; is Vice-President of the Portuguese Society for Psychiatry and Mental Health, and Head of the Psychiatry Working Group for the National Board of Medical Examination (GPNA) at the Portuguese Medical Association and Portuguese Ministry of Health.
Clinical Trial
ISRCTN17965026
Funding Statement
Gabriela RIbeiro was funded by doctoral fellowships from Universidade de Lisboa (BD/2015Call) and Fundacao para a Ciencia e Tecnologia (FCT; SFRH/BD/128783/2017). Gabriela Ribeiro and Albino J.Oliveira-Maia were supported by the Champalimaud Foundation through a Clinical Kickstarter grant. Ana B. Fernandes was supported by a postdoctoral fellowship (SFRH/BPD/880972/2012) and is supported by a postdoctoral contract (DL 57/2016/CP1483/CT0001) and grant (PTDC/SAU-NUT/3507/2021) from FCT. Albino J. Oliveira Maia was supported by grants from the BIAL Foundation (176/10) and from (FCT), through a Junior Research and Career Development Award from the Harvard Medical Portugal Program (HMSP/ICJ/0020/2011), and is funded by a Starting Grant from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. 950357).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of Champalimaud Foundation, Champalimaud Foundation, Lisbon Academic Medical Centre, and Centro Hospitalar Lisboa Ocidental gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
